Stroke - Pipeline Review, H2 2013

Date: July 31, 2013
Pages: 343
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S6B11FFE7A9EN
Leaflet:

Download PDF Leaflet

Stroke - Pipeline Review, H2 2013
Stroke - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Stroke - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Stroke. Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Stroke.
  • A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Stroke pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Stroke.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Stroke Overview
Therapeutics Development
An Overview of Pipeline Products for Stroke
Stroke Therapeutics under Development by Companies
Stroke Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Stroke Therapeutics – Products under Development by Companies
Stroke Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Stroke Therapeutics Development
Johnson & Johnson
Athersys, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Cytokine PharmaSciences, Inc.
CardioVascular BioTherapeutics, Inc.
Isotechnika Pharma Inc.
Acorda Therapeutics, Inc.
Glenmark Pharmaceuticals Ltd.
Jeil Pharmaceutical Co., Ltd.
Laboratoires Pierre Fabre SA
Novavax, Inc.
Pfizer Inc.
Celgene Corporation
Anavex Life Sciences Corp.
Neuralstem, Inc.
Living Cell Technologies Limited
Neuren Pharmaceuticals Limited
Arena Pharmaceuticals, Inc.
ADVENTRX Pharmaceuticals
KOLON LIFE SCIENCE INC.
WhanIn Pharmaceutical Co., Ltd.
RegeneRx Biopharmaceuticals, Inc.
Cytomedix, Inc.
POZEN Inc.
ReNeuron Group plc
Torrent Pharmaceuticals Limited
Dongwha Pharm Co., Ltd.
PhytoHealth Corporation
Pluristem Therapeutics Inc.
MediPost Co., Ltd.
NeuroVive Pharmaceutical AB
StemCells, Inc.
SCYNEXIS, Inc.
KeyNeurotek Pharmaceuticals AG
SynZyme Technologies, LLC
BioMAS Ltd.
Artielle ImmunoTherapeutics, Inc.
Endotis Pharma
AGY Therapeutics, Inc.
Phoenix Biotechnology, Inc.
Regado Biosciences.
Fina Biotech
Xigen SA
Angion Biomedica Corp.
GliaMed, Inc.
Palkion, Inc.
Stemedica Cell Technologies, Inc.
SanBio, Inc.
Diakron Pharmaceuticals, Inc.
Lacer, S.A.
Medistem, Inc.
Embryome Sciences, Inc.
Medestea Research & Production S.p.A.
Encore Therapeutics Inc.
Georgia Tech Research Corporation
Shin Poong Pharm Co., Ltd.
Inserm Transfert SA
ArmaGen Technologies, Inc.
Sinapis Pharma, Inc
CHA Bio & Diostech Co., Ltd.
Vicore Pharma AB
InVasc Therapeutics, Inc.
FCB-Pharmicell Co.,Ltd.
Stempeutics Research Private Limited
America Stem Cell, Inc.
Ampio Pharmaceuticals, Inc.
Stroke – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
GSK-249320 - Drug Profile
GM-1485 - Drug Profile
ANAVEX-2-73 - Drug Profile
ANAVEX-1-41 - Drug Profile
vorapaxar sulfate - Drug Profile
MultiStem - Drug Profile
cenplacel-L - Drug Profile
levomilnacipran hydrochloride SR - Drug Profile
(aspirin EC + omeprazole IR) - Drug Profile
(enteric coated aspirin + immediate release omeprazole) - Drug Profile
CVBT-141F - Drug Profile
RGN-352 - Drug Profile
clopidogrel bisulfate - Drug Profile
DP-4088 - Drug Profile
Cerecellgram-Stroke - Drug Profile
ANAVEX-19-144 - Drug Profile
Anti Platelet Program - Drug Profile
BB-3 - Drug Profile
Neu-2000 - Drug Profile
HIF Stablilizer - Drug Profile
LA-419 - Drug Profile
XG-102 - Drug Profile
dalfampridine - Drug Profile
GGF-2 - Drug Profile
KN-387271 - Drug Profile
AGT-190 - Drug Profile
NNZ-2591 - Drug Profile
PBI-05204 - Drug Profile
methamphetamine - Drug Profile
AS-101 - Drug Profile
TXA-127 - Drug Profile
semapimod - Drug Profile
NA-1 - Drug Profile
Human Neural Stem Cells - Drug Profile
MTP-131 - Drug Profile
arginine hydrochloride - Drug Profile
AGT-115 - Drug Profile
GBR-600 - Drug Profile
PF-03049423 - Drug Profile
RTL For Stroke - Drug Profile
lithium carbonate - Drug Profile
Drug For Stroke - Drug Profile
NSI-189 - Drug Profile
INV-155 - Drug Profile
ReN-001 - Drug Profile
PLX Cells for Ischemic Stroke - Drug Profile
ALD-401 - Drug Profile
AB-002 - Drug Profile
PHN-015 - Drug Profile
CNTO-0007 - Drug Profile
Vascular Program - Drug Profile
NSI-566RSC - Drug Profile
NTCELL - Drug Profile
PanCyte - Drug Profile
Cell Therapy For Stroke - Drug Profile
DMI-4983 - Drug Profile
LA-8045 - Drug Profile
Compound-21 - Drug Profile
poloxamer - Drug Profile
HYNR-CS - Drug Profile
AU-01 - Drug Profile
ND-478 - Drug Profile
NVP-014 - Drug Profile
NVP-016 - Drug Profile
NVP-017 - Drug Profile
KLS-Nst - Drug Profile
filgrastim - Drug Profile
NR-2A Modulators - Drug Profile
WIB-801C - Drug Profile
Angiostem Derivatives - Drug Profile
COR-3 - Drug Profile
COR-2 - Drug Profile
EP-37 - Drug Profile
ANG-3186 - Drug Profile
NT-KC-005 - Drug Profile
F-637 - Drug Profile
PR-15 - Drug Profile
JPI-289 - Drug Profile
ThermoStem Program - Drug Profile
APT-102 - Drug Profile
Cyclophilin Inhibitory Compounds - Drug Profile
E-Selectin Tolerogen - Drug Profile
Drug Targeting AGY-208 - Drug Profile
Stroke Program - Drug Profile
Drug Targeting AGY-221 - Drug Profile
Drug Targeting AGY-220 - Drug Profile
Drug Targeting AGY-218 - Drug Profile
Drug Targeting AGY-207 - Drug Profile
EPO-Variant - Drug Profile
erythropoietin - Drug Profile
Bone Marrow Stromal Cells - Drug Profile
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile
TRC-051384 - Drug Profile
Drug For Ischemic Stroke - Drug Profile
SP-8203 - Drug Profile
miR-29b - Drug Profile
ABHxD-I - Drug Profile
P2Y Purinergic Receptor Agonist - Drug Profile
Dihydroxyflavone - Drug Profile
Glycogen Synthase Kinase 3 Inhibitors - Drug Profile
BLI-1009 - Drug Profile
Neuronal Stem Cells - Drug Profile
Iacvita - Drug Profile
Mutated Tissue Plasminogen Activator - Drug Profile
GNR-014 - Drug Profile
Apotransferrin - Drug Profile
EDNOL-202 - Drug Profile
Stroke Therapy - Drug Profile
Endothelial Progenitor Cells - Drug Profile
Neural Stem Cells - Drug Profile
NPC Program - Drug Profile
cycloserine - Drug Profile
T-33 - Drug Profile
Lipophilic Phenolic Antioxidants - Drug Profile
Tetraamine derivatives - Drug Profile
Stem Cell Therapy For Treating Stroke - Drug Profile
Aza-Peptide Epoxides - Drug Profile
AB-144 - Drug Profile
Cerecellgram For Hemorrhagic Stroke - Drug Profile
Stroke Therapeutics – Drug Profile Updates
Stroke Therapeutics – Discontinued Products
Stroke Therapeutics - Dormant Products
Stroke – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Stroke, H2 2013
Products under Development for Stroke – Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Number of Products under Development by Companies, H2 2013 (Contd..2)
Number of Products under Development by Companies, H2 2013 (Contd..3)
Number of Products under Development by Companies, H2 2013 (Contd..4)
Number of Products under Development by Companies, H2 2013 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Products under Development by Companies, H2 2013 (Contd..2)
Products under Development by Companies, H2 2013 (Contd..3)
Products under Development by Companies, H2 2013 (Contd..4)
Products under Development by Companies, H2 2013 (Contd..5)
Products under Development by Companies, H2 2013 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2013
Johnson & Johnson, H2 2013
Athersys, Inc., H2 2013
GlaxoSmithKline plc, H2 2013
Merck & Co., Inc., H2 2013
Cytokine PharmaSciences, Inc., H2 2013
CardioVascular BioTherapeutics, Inc., H2 2013
Isotechnika Pharma Inc., H2 2013
Acorda Therapeutics, Inc., H2 2013
Glenmark Pharmaceuticals Ltd., H2 2013
Jeil Pharmaceutical Co., Ltd., H2 2013
Laboratoires Pierre Fabre SA, H2 2013
Novavax, Inc., H2 2013
Pfizer Inc., H2 2013
Celgene Corporation, H2 2013
Anavex Life Sciences Corp., H2 2013
Neuralstem, Inc., H2 2013
Living Cell Technologies Limited, H2 2013
Neuren Pharmaceuticals Limited, H2 2013
Arena Pharmaceuticals, Inc., H2 2013
ADVENTRX Pharmaceuticals, H2 2013
KOLON LIFE SCIENCE INC., H2 2013
WhanIn Pharmaceutical Co., Ltd., H2 2013
RegeneRx Biopharmaceuticals, Inc., H2 2013
Cytomedix, Inc., H2 2013
POZEN Inc., H2 2013
ReNeuron Group plc, H2 2013
Torrent Pharmaceuticals Limited, H2 2013
Dongwha Pharm Co., Ltd., H2 2013
PhytoHealth Corporation, H2 2013
Pluristem Therapeutics Inc., H2 2013
MediPost Co., Ltd., H2 2013
NeuroVive Pharmaceutical AB, H2 2013
StemCells, Inc., H2 2013
SCYNEXIS, Inc., H2 2013
KeyNeurotek Pharmaceuticals AG, H2 2013
SynZyme Technologies, LLC, H2 2013
BioMAS Ltd., H2 2013
Artielle ImmunoTherapeutics, Inc., H2 2013
Endotis Pharma, H2 2013
AGY Therapeutics, Inc., H2 2013
Phoenix Biotechnology, Inc., H2 2013
Regado Biosciences., H2 2013
Fina Biotech, H2 2013
Xigen SA, H2 2013
Angion Biomedica Corp., H2 2013
GliaMed, Inc., H2 2013
Palkion, Inc., H2 2013
SanBio, Inc., H2 2013
Diakron Pharmaceuticals, Inc., H2 2013
Lacer, S.A., H2 2013
Medistem, Inc., H2 2013
Embryome Sciences, Inc., H2 2013
Medestea Research & Production S.p.A., H2 2013
Encore Therapeutics Inc., H2 2013
Georgia Tech Research Corporation, H2 2013
Shin Poong Pharm Co., Ltd., H2 2013
Inserm Transfert SA, H2 2013
ArmaGen Technologies, Inc., H2 2013
Sinapis Pharma, Inc, H2 2013
CHA Bio & Diostech Co., Ltd., H2 2013
Vicore Pharma AB, H2 2013
InVasc Therapeutics, Inc., H2 2013
FCB-Pharmicell Co.,Ltd., H2 2013
America Stem Cell, Inc., H2 2013
Ampio Pharmaceuticals, Inc., H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Stroke Therapeutics – Drug Profile Updates
Stroke Therapeutics – Discontinued Products
Stroke Therapeutics – Dormant Products
Stroke Therapeutics – Dormant Products (Contd..1)
Stroke Therapeutics – Dormant Products (Contd..2)
Stroke Therapeutics – Dormant Products (Contd..3)
Stroke Therapeutics – Dormant Products (Contd..4)

LIST OF FIGURES

Number of Products under Development for Stroke, H2 2013
Products under Development for Stroke – Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Acute Ischemic Stroke - Pipeline Review, H2 2013 US$ 2,000.00 Aug, 2013 · 103 pages
Acute Ischemic Stroke - Pipeline Review, Q1 2011 US$ 500.00 Feb, 2011 · 61 pages
Stroke - Pipeline Review, Q3 2011 US$ 500.00 Jul, 2011 · 193 pages
FASgen, Inc. – Product Pipeline Review – 2012 US$ 1,500.00 Nov, 2012 · 27 pages

Ask Your Question

Stroke - Pipeline Review, H2 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: